Mallinckrodt completes sale of BioVectra for up to $250M
Mallinckrodt has completed the sale of its wholly owned subsidiary BioVectra to an affiliate of H.I.G. Capital, a leading global private equity investment firm.
The terms of the transaction were updated since initial announcement, with total consideration of up to $250 million including an upfront payment of $135 million and contingent consideration of $115 million based on the long-term performance of the business.
"This transaction marks an advancement of Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals," said Mark Trudeau, president and CEO. "While we recognize the longer-term growth potential of BioVectra, we believe this company will best achieve its potential under H.I.G. Capital, and we are confident that this sale will enable us to participate financially in the future success of the business."
BioVectra is a contract development and manufacturing organization that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients